Universe Pharmaceuticals Inc (UPC)

$3.71

-0.24

(-6.08%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $3.20
    $4.03
    $3.71
    downward going graph

    13.75%

    Downside

    Day's Volatility :20.6%

    Upside

    7.94%

    downward going graph
  • $0.75
    $4.32
    $3.71
    downward going graph

    79.78%

    Downside

    52 Weeks Volatility :82.64%

    Upside

    14.12%

    downward going graph

Returns

PeriodUniverse Pharmaceuticals IncIndex (Russel 2000)
3 Months
90.26%
0.0%
6 Months
73.36%
0.0%
1 Year
68.94%
0.0%
3 Years
-76.67%
-20.8%

Highlights

Market Capitalization
14.4M
Book Value
$10.91
Earnings Per Share (EPS)
-1.7
Profit Margin
-19.08%
Operating Margin TTM
-26.56%
Return On Assets TTM
-3.91%
Return On Equity TTM
-14.34%
Revenue TTM
32.3M
Revenue Per Share TTM
8.91
Quarterly Revenue Growth YOY
-13.200000000000001%
Gross Profit TTM
21.9M
EBITDA
-3.0M
Diluted Eps TTM
-1.7
Quarterly Earnings Growth YOY
-0.82
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Company Financials

FY18Y/Y Change
Revenue
28.5M
-
Net Income
7.6M
-
Net Profit Margin
26.66%
-
FY19Y/Y Change
Revenue
33.2M
↑ 16.54%
Net Income
7.6M
↓ 0.68%
Net Profit Margin
22.73%
↓ 3.93%
FY20Y/Y Change
Revenue
30.7M
↓ 7.6%
Net Income
7.6M
↑ 0.09%
Net Profit Margin
24.62%
↑ 1.89%
FY21Y/Y Change
Revenue
48.0M
↑ 56.27%
Net Income
11.3M
↑ 49.77%
Net Profit Margin
23.59%
↓ 1.03%
FY22Y/Y Change
Revenue
40.1M
↓ 16.34%
Net Income
-8.7M
↓ 177.18%
Net Profit Margin
-21.76%
↓ 45.35%
FY23Y/Y Change
Revenue
32.3M
↓ 19.52%
Net Income
-6.2M
↓ 29.46%
Net Profit Margin
-19.08%
↑ 2.68%
Q2 FY22Q/Q Change
Revenue
24.2M
-
Net Income
1.7M
-
Net Profit Margin
7.16%
-
Q4 FY22Q/Q Change
Revenue
15.9M
-
Net Income
-10.5M
-
Net Profit Margin
-65.67%
-
Q2 FY23Q/Q Change
Revenue
18.5M
-
Net Income
-715.4K
-
Net Profit Margin
-3.87%
-
Q4 FY23Q/Q Change
Revenue
13.8M
↓ 25.05%
Net Income
-5.4M
↑ 661.45%
Net Profit Margin
-39.36%
↓ 35.49%
FY18Y/Y Change
Total Assets
28.1M
-
Total Liabilities
18.4M
-
FY19Y/Y Change
Total Assets
17.8M
↓ 36.48%
Total Liabilities
5.5M
↓ 70.36%
FY20Y/Y Change
Total Assets
28.8M
↑ 61.49%
Total Liabilities
8.0M
↑ 46.74%
FY21Y/Y Change
Total Assets
70.1M
↑ 143.52%
Total Liabilities
11.2M
↑ 40.11%
FY22Y/Y Change
Total Assets
59.5M
↓ 15.12%
Total Liabilities
13.1M
↑ 16.83%
FY23Y/Y Change
Total Assets
53.3M
↓ 10.5%
Total Liabilities
13.8M
↑ 5.01%
Q3 FY22Q/Q Change
Total Assets
59.5M
↓ 16.57%
Total Liabilities
13.1M
↑ 28.31%
Q4 FY22Q/Q Change
Total Assets
59.5M
↑ 0.0%
Total Liabilities
13.1M
↑ 0.0%
Q1 FY23Q/Q Change
Total Assets
70.4M
↑ 18.19%
Total Liabilities
23.2M
↑ 77.45%
Q2 FY23Q/Q Change
Total Assets
70.4M
↑ 0.0%
Total Liabilities
23.2M
↑ 0.0%
Q3 FY23Q/Q Change
Total Assets
53.3M
↓ 24.27%
Total Liabilities
13.8M
↓ 40.82%
Q4 FY23Q/Q Change
Total Assets
53.3M
↑ 0.0%
Total Liabilities
13.8M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
4.5M
-
Investing Cash Flow
-145.1K
-
Financing Cash Flow
-4.9M
-
FY19Y/Y Change
Operating Cash Flow
13.2M
↑ 196.34%
Investing Cash Flow
-86.0K
↓ 40.71%
Financing Cash Flow
-16.0M
↑ 225.64%
FY20Y/Y Change
Operating Cash Flow
6.1M
↓ 53.69%
Investing Cash Flow
-51.8K
↓ 39.79%
Financing Cash Flow
470.1K
↓ 102.94%
FY21Y/Y Change
Operating Cash Flow
-2.1M
↓ 133.62%
Investing Cash Flow
-27.1M
↑ 52141.32%
Financing Cash Flow
26.6M
↑ 5554.07%
FY22Y/Y Change
Operating Cash Flow
-1.3M
↓ 36.17%
Investing Cash Flow
-3.9M
↓ 85.56%
Financing Cash Flow
3.3M
↓ 87.52%
Q2 FY22Q/Q Change
Operating Cash Flow
6.1M
↑ 100.0%
Investing Cash Flow
-1.9M
↑ 6893.78%
Financing Cash Flow
-20.0K
↑ 99.99%
Q3 FY22Q/Q Change
Operating Cash Flow
-3.7M
↓ 160.72%
Investing Cash Flow
-1.9M
↑ 0.0%
Financing Cash Flow
1.7M
↓ 8448.6%
Q4 FY22Q/Q Change
Operating Cash Flow
-7.9M
↑ 112.66%
Investing Cash Flow
-323.0
↓ 99.98%
Financing Cash Flow
3.3M
↑ 100.0%
Q1 FY23Q/Q Change
Operating Cash Flow
2.4M
↓ 130.37%
Investing Cash Flow
-323.0
↑ 0.0%
Financing Cash Flow
1.0M
↓ 68.83%

Technicals Summary

Sell

Neutral

Buy

Universe Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Universe Pharmaceuticals Inc
Universe Pharmaceuticals Inc
41.06%
73.36%
68.94%
-76.67%
-86.98%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.26%
4.21%
47.47%
49.15%
67.79%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
3.97%
5.95%
0.22%
20.24%
20.24%
Zoetis Inc.
Zoetis Inc.
4.38%
-6.6%
-2.69%
-9.83%
54.03%
Viatris Inc.
Viatris Inc.
13.09%
1.72%
12.98%
-15.79%
-27.54%
Catalent, Inc.
Catalent, Inc.
2.5%
16.24%
21.69%
-49.0%
5.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Universe Pharmaceuticals Inc
Universe Pharmaceuticals Inc
NA
NA
NA
0.0
-0.14
-0.04
NA
10.91
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.17
39.17
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.7
29.7
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.47
34.47
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Universe Pharmaceuticals Inc
Universe Pharmaceuticals Inc
NA
$14.4M
-86.98%
NA
-19.08%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.5B
67.79%
39.17
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.7B
20.24%
29.7
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$81.8B
54.03%
34.47
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.9B
-27.54%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
5.41%
211.02
-28.44%

Insights on Universe Pharmaceuticals Inc

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 49.2% return, outperforming this stock by 125.9%

Institutional Holdings

  • UBS Group AG

    0.03%
  • Acadian Asset Management LLC

    0.01%

Company Information

Organization
Universe Pharmaceuticals Inc
Employees
225
CEO
Mr. Gang Lai
Industry
Miscellaneous

FAQs